AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
RATIONALE: AMG 706 and octreotide may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth and by blocking blood flow to the tumor.
PURPOSE: This phase II trial is studying how well AMG 706 and octreotide work in treating
patients with low-grade neuroendocrine tumors.